Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Symphogen initiates phase I/II trial of Sym-015 in advanced solid tumor malignancies

March 21, 2016

Ono seeks Japanese approval of Opdivo for relapsed or refractory Hodgkin's lymphoma

March 21, 2016

Mologen announces extension of TEACH study

March 17, 2016

Data presented on brentuximab vedotin in germ-cell tumors

March 17, 2016

DSMB recommends continuation of phase II trial of lirilumab in elderly patients with AML

March 16, 2016

Immunomedics terminates phase III PANCRIT-1 trial for clivatuzumab tetratexan

March 16, 2016

BioInvent and Oncurious partner with research consortium for phase I/IIa study of TB-403

March 15, 2016

FDA grants priority review to atezolizumab BLA for advanced bladder cancer

March 15, 2016

Medigene cleared to advance DC vaccine trial to phase II

March 14, 2016

Novartis submits sBLA for ofatumumab with fludarabine and cyclophosphamide for relapsed CLL

March 11, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...